Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Joel Leong

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
ACS Infectious Diseases|September 15, 2016
Cryptosporidiosis Drug Discovery: Opportunities and ChallengesUjjini H Manjunatha, Alexander T Chao, F Joel Leong, et al.
Journal of Neuromuscular Diseases|April 1, 2025
A neuromuscular clinician's primer on machine learningCrystal Jing Jing Yeo, Savitha Ramasamy, F Joel Leong, et al.
Malaria Journal|January 7, 2018
A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquineF Joel Leong, Jay Prakash Jain, Yiyan Feng, et al.
Antimicrobial Agents and Chemotherapy|August 20, 2014
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteersF Joel Leong, Rong Zhao, Shuqi Zeng, et al.
Antimicrobial Agents and Chemotherapy|August 13, 2014
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteersF Joel Leong, Ruobing Li, Jay Prakash Jain, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 6, 2005
Improving influx constant and ratio estimation in FDOPA brain PET analysis for Parkinson's diseaseXiao-Bo Pan, Thomas G Wright, F Joel Leong, et al.
Antimicrobial Agents and Chemotherapy|June 21, 2017
Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy VolunteersJay Prakash Jain, F Joel Leong, Lan Chen, et al.
The New England Journal of Medicine|July 31, 2014
Spiroindolone KAE609 for falciparum and vivax malariaNicholas J White, Sasithon Pukrittayakamee, Aung Pyae Phyo, et al.
The New England Journal of Medicine|September 23, 2016
Antimalarial Activity of KAF156 in Falciparum and Vivax MalariaNicholas J White, Tran T Duong, Chirapong Uthaisin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 10, 2020
Safety, Pharmacokinetics, and Causal Prophylactic Efficacy of KAF156 in a Plasmodium falciparum Human Infection StudyJames G Kublin, Sean C Murphy, Janine Maenza, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
ACS Infectious Diseases|September 15, 2016
Cryptosporidiosis Drug Discovery: Opportunities and ChallengesUjjini H Manjunatha, Alexander T Chao, F Joel Leong, et al.
Journal of Neuromuscular Diseases|April 1, 2025
A neuromuscular clinician's primer on machine learningCrystal Jing Jing Yeo, Savitha Ramasamy, F Joel Leong, et al.
Malaria Journal|January 7, 2018
A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquineF Joel Leong, Jay Prakash Jain, Yiyan Feng, et al.
Antimicrobial Agents and Chemotherapy|August 20, 2014
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteersF Joel Leong, Rong Zhao, Shuqi Zeng, et al.
Antimicrobial Agents and Chemotherapy|August 13, 2014
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteersF Joel Leong, Ruobing Li, Jay Prakash Jain, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 6, 2005
Improving influx constant and ratio estimation in FDOPA brain PET analysis for Parkinson's diseaseXiao-Bo Pan, Thomas G Wright, F Joel Leong, et al.
Antimicrobial Agents and Chemotherapy|June 21, 2017
Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy VolunteersJay Prakash Jain, F Joel Leong, Lan Chen, et al.
The New England Journal of Medicine|July 31, 2014
Spiroindolone KAE609 for falciparum and vivax malariaNicholas J White, Sasithon Pukrittayakamee, Aung Pyae Phyo, et al.
The New England Journal of Medicine|September 23, 2016
Antimalarial Activity of KAF156 in Falciparum and Vivax MalariaNicholas J White, Tran T Duong, Chirapong Uthaisin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 10, 2020
Safety, Pharmacokinetics, and Causal Prophylactic Efficacy of KAF156 in a Plasmodium falciparum Human Infection StudyJames G Kublin, Sean C Murphy, Janine Maenza, et al.
Pageof 2